EXCLUSIVE: Vivani Medical Tells Benzinga Co. Announces FDA Clears Investigational New Drug Application And Lifts Clinical Hold For NPM-119, A Miniature Long-Term Subdermal GLP-1 Drug Implant
Portfolio Pulse from Benzinga Newsdesk
Vivani Medical announced that the FDA has cleared its Investigational New Drug (IND) application and lifted the clinical hold for NPM-119, a miniature long-term subdermal GLP-1 drug implant.
June 13, 2024 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivani Medical received FDA clearance for its IND application and the lifting of the clinical hold for NPM-119, a subdermal GLP-1 drug implant.
The FDA clearance and lifting of the clinical hold are significant milestones for Vivani Medical, likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100